Targeted Agent and Profiling Utilization Registry (TAPUR) 

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Eligibility Requirements

patients 18 years old and up

Locally advanced or metastatic solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma 

Principal Investigator

Deepti Behl, MD

Funder

American Society of Clinical Oncology